Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIC: Epigenetic Evaluation of HAT/HDAC Activity in CIS
NCT02862301Unknown
- Sponsor
- CHU de Besançon
- Start
- Apr 2016
- Primary completion
- Jun 2020
- Countries
- 1
01
Overview
Trial (2 arms), sponsored by CHU de Besançon. Primary endpoint: HDAC/ HAT enzymatic activity (ratio) at Day 0. Status: unknown.
Beyond the preview
Go deeper on NCT02862301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02862301.